Cabozantinib active in non clear mRCC: great to see Andy Hahn Nieves together in the study led by Lauren Harshman IMDC #ASCO18 ASCO

One of the most gigantic and collaborative efforts in RCC field with #PROSPER with lots of correlatives built in—we need your help! Kudos to Lauren Harshman Mohamad Allaf ECOG-ACRIN Cancer Research Group and many others @IKCCtrials IKCC Kidney Cancer KCCure Kidney Cancer Kidney Cancer

Congrats Dominick Bossé, MD MPH (w mentorship from Toni Choueiri, MD) on association between key #KidneyCancer genes (eg PBRM1, BAP1) and clinical outcome. Nice summary from Eric Jonasch MD Anderson Cancer Center.

TP53, PTEN, RB1 associated with poor prognosis in CSPC and CRPC by Anis Hamid & Christopher Sweeney, MBBS. Amazing work! Dana-Farber Eli Van Allen Atish Choudhury, MD PhD @belowthebelt_md

Proud of Nieves sharing the results from largest dataset on #cabozantinib in non-clear cell #kidneycancer Many great colleagues' contributed! #asco18 @danafarber

Dan George shootout for #PROSPER #RCC why perhaps treating before surgery makes sense in IO trials #neoantigens Lauren Harshman ASCO Mohamad Allaf #ASCO18

#PDG4 team supporting Capu B #MCCRWorkshop #voteforCapu #spanishoncologist Nieves Pmartinromano Gustave Roussy x.com/pmartinromano/…

Study from @sloan_kettering shows that ~20% of non-cc mRCC pts have germline mutations. Editorial in JAMA Oncology by Kathleen Cooney raises question whether all non-cc mRCC pts should be referred for germline testing? bit.ly/2ucJd20 Neeraj Agarwal, MD, FASCO Sumanta K. Pal, MD, FASCO

Excellent example of persistent & perseverance by Lauren Harshman with #EA8143 PROSPER trial that is actively ongoing in numerous sites in US and soon Canada. Way to go! ECOG-ACRIN Cancer Research Group Dana-Farber Toni Choueiri, MD Sumanta K. Pal, MD, FASCO Suzanne Cole, MD, FACP, FASCO Hamid Emamekhoo Bradley McGregor KCCure Kidney Cancer

Thanks!! And also a big thanks to my mentor Lauren Harshman & team Dana-Farber

Pre-existing autoimmune disorders: safety and activity of #immunotherapy in #RCC pts Great study Nieves Xiao Wei, MD Bradley McGregor Toni Choueiri, MD Lauren Harshman Dana-Farber #IKCS18

Article online: retrospective, cohort study on #cabozantinib in advanced non-clear-cell #renalcellcarcinoma thelancet.com/journals/lanon…

Thanks for highlighting. Multi-institutional collaboration. Thanks to all included! thelancet.com/journals/lanon…

Collaboration +persistence +awesome RCC international community —congrats ⁦Lauren Harshman⁩ ⁦Nieves⁩ and everyone ! ⁦Dana-Farber⁩ ⁦Dana-Farber News⁩ thelancet.com/journals/lanon…

Emily 🙏Emily for sharing! ☑️ Heterogeneity in HPD defn across studies (different TGR formulas + TGR ratio cutoffs) ☑️ New lesions not accounted for in most defns ☑️ Underlying biology remains unclear Nieves Lauren Harshman Osama Rahma Eric Ko, MD PhD Toni Choueiri, MD

Stellar speakers for the upcoming cycle of “Meet the Oncology Expert” seminars at Institut Jules Bordet Instituut

Not half bad 👏 Christopher Sweeney, MBBS #ENZAMET ANZUP Dana-Farber News #ASCO19

Amazing poster by our star fellow Anis Hamid mentored by Christopher Sweeney, MBBS about genomic predictors of CRPC clinical benefit in next generation hormonal therapy! Misha Beltran Atish Choudhury, MD PhD ASCO #ASCO19 Weill Cornell Medicine Dana-Farber Dana-Farber News

🚩POSTER SESSION ASCO #ASCO19 📆Monday 🕐 ‼️A new study characterizes the safety of checkpoint inhibitors in patients w autoimmune disorders, providing hope for more advanced care options for such pts Nieves Toni Choueiri, MD Lauren Harshman meetinglibrary.asco.org/record/172119/…

Back to #Twitter in time for the high level event of hosting joaquim bellmunt from Harvard Medical School for the Institut Jules Bordet Instituut Université libre de Bruxelles Meet the Oncology Expert seminar on #BladderCancer. A privilege and a great pleasure!